Analysis and Therapy of Age-Dependent Proteostasis Failure in Neurodegeneration
神经变性中年龄依赖性蛋白质稳态失败的分析和治疗
基本信息
- 批准号:8666527
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylationAcylationAdherenceAffectAgeAlzheimer&aposs DiseaseAmyloidAmyotrophic Lateral SclerosisAnimal ModelAntibodiesAntioxidantsAppearanceAssesAtaxiaAutophagocytosisBiological ModelsBrainCaenorhabditis elegansCell RespirationCellsCentral Nervous System PartChemical AgentsChemicalsCleaved cellClinicalCodon NucleotidesComplexCraniocerebral TraumaDefectDementiaDetergentsDiagnosticDiseaseDrug Metabolic DetoxicationElderlyEquilibriumExposure toFailureFamilial diseaseGenerationsGenesGeneticHealthHumanHuntington DiseaseIndividualIonsLabelLeadLearningLengthLesionLinkMAPK8 geneMaintenanceMitochondriaModelingModificationMolecularMolecular ChaperonesMusMutationNematodaNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesNeuronsNeuropathyNeurotoxinsParkinson DiseaseParkinson&aposs DementiaPathway interactionsPatientsPeptide FragmentsPeptidesPharmaceutical PreparationsPhosphorylationPlayPost-Translational Protein ProcessingProceduresProcessPropertyProteinsPsyche structureRNA InterferenceRecyclingRelative (related person)ReportingResearch ProposalsRiskRoleSamplingScanningSeveritiesSignal PathwaySiteSpecificityStable Isotope LabelingStructural ProteinStructureSuperoxide DismutaseSystemTemperatureTestingTherapeuticTissue SampleTissuesToxic Environmental SubstancesToxic effectToxicant exposureTransgenesTransgenic OrganismsTrinucleotide RepeatsTriplet Multiple BirthTrypsinUbiquitinValidationVeteransViralage relatedbasebrain cellcatalaseclinical Diagnosisclinically relevantcomparativecrosslinkdesigngel electrophoresisglycationhuman FRAP1 proteinimprovedin vivomind controlmulticatalytic endopeptidase complexneuropathologyneurotoxicneurotoxicityoxidationoxidative damagepolyglutaminepreventprotein TDP-43protein aggregateprotein aggregationprotein complexprotein misfoldingrepairedrepositorysynucleintau Proteinsubiquilin
项目摘要
DESCRIPTION (provided by applicant):
Most major neurodegenerative diseases are characterized by the formation of toxic protein aggregates which compromise a specific part of the central nervous system. Clinical diagnosis has been guided by the regions affected, but it is becoming increasingly evident that the basic processes underlying Alzheimer dementia are remarkably similar to those leading to Parkinson's and Huntington's diseases, and Amyotrophic Lateral Sclerosis. Although all cells are obliged to maintain proteostatic equilibrium, neurons are at particular risk due to high rates of oxidative metabolism. Specific genetic lesions (or possibly chemical or viral exposure, in sporadic cases) may determine the site of neuropathy as the "weakest link" based on the balance of pro- aggregation and countervailing factors. Factors favoring aggregation include high local abundance of vulnerable proteins and structural instability (determined by the native folded structure, exposed reactive groups, and triplet-array length, if present), oxidative damage, glycation, and protein-reactive metabolites or environmental toxicants that produce cross-linking or adduction. Protective factors include antioxidant defenses (SODs, GSTs, catalases, etc.), detoxification/clearance systems, levels of HSP/chaperones to refold transiently misfolded proteins (preventing their adherence to aggregates via exposed hydrophobic residues), protein repair of covalent molecular damage that would favor misfolding, and proteasomal degradation of ubiquitinylated proteins. Autophagy may be able to clear the large insoluble aggregates diagnostic of these neuropathologies, but it remains controversial whether those are indeed the most neurotoxic complexes, or are instead less-toxic, sequestered repositories formed from smaller, soluble aggregates which are more potent neurotoxins. This issue could be resolved through a careful, comparative analysis of soluble vs. insoluble aggregates, "seeded" by several of the diverse initiator proteins observed in neuropathies, defining proteins and post-translational modifications in C. elegans and human neuropathology samples. The current proposal has three intertwined and complementary aims: (1.) To define proteins that aggregate in C. elegans models of Alzheimer's, initiated or seeded by neuron-specific tau and Ass transgenes. Protein complexes from nematodes with age-dependent or induced aggregates will be pulled down with antibody to tau or Ass, and then separated into detergent-insoluble and soluble fractions. Proteins from each fraction will be resolved by gel electrophoresis, and peptides will be cleaved by trypsin and analyzed by LC-MS2 to define and quantify the proteins and their post-synthetic modifications. The most sensitive and reliable quantitation uses product-ion scans to seek diagnostic fragments from predicted peptides; in parallel, we will also conduct more general but less sensitive "unbiased scans" to identify and quantify the more abundant proteins, even if unforeseen. Results will be cross-checked and extended by unrestrictive searches to quantify postsynthetic modifications including phosphorylation, acetylation, oxidation, acylation, glycation, etc., and thus implicate mechanisms involved in their
age-dependent occurrence. Dual-label procedures will allow robust relative quantitation, and the validation of proteins that aggregated in vivo rather than during handling. (2.) To seek similar aggregates in human samples. De-identified samples from affected and control brain sites from AD subjects will be studied along with comparable-site samples from normal controls, and their aggregates immunoprecipitated with antibodies to Ass and tau. Complexes will be fractionated and separated as for Aim 1, and aggregates subjected to LC-MS2 analyses as above, seeking protein markers or modifications including any were implicated in the C. elegans models. (3.) To assess which implicated proteins and modifications play functional roles in neurotoxicity, it will be made worse by RNA interference targeting protective genes, or relieved by therapeutic drugs or RNAi against pro-aggregative genes. Proteins or modifications in either soluble or insoluble aggregates, which vary concordantly with neurotoxicity, become functional candidates
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Joseph Shmookler Reis其他文献
Robert Joseph Shmookler Reis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert Joseph Shmookler Reis', 18)}}的其他基金
Analysis and Therapy of Age-Dependent Proteostasis Failure in Neurodegeneration
神经变性中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
8971964 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Analysis and Therapy of Age-Dependent Proteostasis Failure in Neurodegeneration
神经变性中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
8803314 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Analysis and therapy of age-dependent proteostasis failure in neurodegeneration
神经退行性变中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
10474260 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Analysis and Therapy of Age-Dependent Proteostasis Failure in Neurodegeneration
神经变性中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
8443076 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Analysis and therapy of age-dependent proteostasis failure in neurodegeneration
神经退行性变中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
10082413 - 财政年份:2013
- 资助金额:
-- - 项目类别:
GENES AFFECTING METABOLISM AND LONGEVITY IN C. ELEGANS
影响线虫新陈代谢和寿命的基因
- 批准号:
7388808 - 财政年份:2007
- 资助金额:
-- - 项目类别:
相似海外基金
Greasing endocytosis in plants - understanding the role of S-acylation in receptor kinase function and internalisation
植物中的润滑内吞作用 - 了解 S-酰化在受体激酶功能和内化中的作用
- 批准号:
BB/Y003756/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Ghrelin de-acylation inhibitors as novel compounds for Parkinson's dementia
生长素释放肽去酰化抑制剂作为治疗帕金森痴呆症的新型化合物
- 批准号:
MR/Y503435/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
S-acylation-dependent regulation of cytokine receptor signaling and cardiac maladaptation
细胞因子受体信号传导和心脏适应不良的 S-酰化依赖性调节
- 批准号:
10561406 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Comprehensive analysis of acidic patch binder using histone acylation catalysts
使用组蛋白酰化催化剂综合分析酸性贴片粘合剂
- 批准号:
22KJ1113 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for JSPS Fellows
S-Acylation of transmembrane proteins in the early secretory pathway
早期分泌途径中跨膜蛋白的 S-酰化
- 批准号:
BB/X001504/1 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Research Grant
N-terminal acylation and sorting of Helicobacter pylori lipoproteins and their role in host response to infection
幽门螺杆菌脂蛋白的 N 末端酰化和分选及其在宿主感染反应中的作用
- 批准号:
10584620 - 财政年份:2022
- 资助金额:
-- - 项目类别:
The Molecular Mechanisms of Glycolytic Enzyme S-acylation in Neurons
神经元糖酵解酶S-酰化的分子机制
- 批准号:
576016-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Anti-CRISPR-mediated Acylation and Bioreversible Esterification for Precision Genome Editing
用于精准基因组编辑的抗 CRISPR 介导的酰化和生物可逆酯化
- 批准号:
10657417 - 财政年份:2022
- 资助金额:
-- - 项目类别:
High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation Reader
YEATS2 组蛋白酰化酶抑制剂的高通量筛选
- 批准号:
10389517 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Roles of KAT8 complexes in governing histone acylation and mouse cerebral development
KAT8复合物在控制组蛋白酰化和小鼠大脑发育中的作用
- 批准号:
RGPIN-2019-07122 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual